Related Experiment Video
Updated: Jul 18, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Progress toward the discovery and development of efficacious BACE inhibitors
Timothy B Durham1, Timothy A Shepherd
1Eli Lilly & Co, Lilly Corporate Center, Indianapolis, IN 46285, USA. durhamti@lilly.com
Abstract:
BACE (beta-site amyloid precursor protein [APP] cleavage enzyme) is a transmembrane aspartyl protease responsible for the first cleavage event in the processing of APP to Abeta peptide. Amyloid plaques composed of Abeta peptides are hypothesized to be the root cause of neuronal cell death in Alzheimer's disease patients. Thus, BACE has become a target of significant interest for pharmaceutical and academic research. The recent literature relating to the discovery and development of efficacious BACE inhibitors is reviewed with particular emphasis on the patent literature.
Related Concept Videos
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets
Preclinical Development: Overview
Inhibitors of Viral Protein Synthesis

